Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Muñoz-Martínez Sergio, Sapena Victor, Forner Alejandro, Bruix Jordi, Sanduzzi-Zamparelli Marco, Ríos José, Bouattour Mohamed, El-Kassas Mohamed, Leal Cassia R G, Mocan Tudor, Nault Jean-Charles, Alves Rogerio C P, Reeves Helen L, da Fonseca Leonardo, García-Juárez Ignacio, Pinato David J, Varela María, Alqahtani Saleh A, Alvares-da-Silva Mario R, Bandi Juan C, Rimassa Lorenza, Lozano Mar, González Santiago Jesús M, Tacke Frank, Sala Margarita, Anders María, Lachenmayer Anja, Piñero Federico, França Alex, Guarino Maria, Elvevi Alessandra, Cabibbo Giuseppe, Peck-Radosavljevic Markus, Rojas Ángela, Vergara Mercedes, Braconi Chiara, Pascual Sonia, Perelló Christie, Mello Vivianne, Rodríguez-Lope Carlos, Acevedo Juan, Villani Rosanna, Hollande Clemence, Vilgrain Valérie, Tawheed Ahmed, Ferguson Theodoro Carmem, Sparchez Zeno, Blaise Lorraine, Viera-Alves Daniele E, Watson Robyn, Carrilho Flair J, Moctezuma-Velázquez Carlos, D'Alessio Antonio, Iavarone Massimo, Reig Maria
Аннотация
METHODS: Multicentre retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February and December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered.
RESULTS: Two hundred fifty patients from 38 centres were included, 218 with hepatocellular carcinoma (HCC) and 32 with intrahepatic cholangiocarcinoma (iCCA). The median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 (IQR: 1.84-11.24) months, 100 (40%) patients have died, 48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage (6.10% [95% CI 2.24-12.74], 11.76% [95% CI 4.73-22.30], 20.69% [95% CI 11.35-31.96] and 34.52% [95% CI 17.03-52.78] for BCLC 0/A, B, C and D, respectively; p = .0017). The hazard ratio was 1.45 (95% CI 0.49-4.31; p = .5032) in BCLC-B versus 0/A, and 3.13 (95% CI 1.29-7.62; p = .0118) in BCLC-C versus 0/A in the competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, and 12 deaths were related to SARS-CoV-2 infection.
CONCLUSIONS: This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period.